Protagonist Therapeutics (NASDAQ: PTGX)
Protagonist Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Protagonist Therapeutics Company Info
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
News & Analysis
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Why Shares of Protagonist Therapeutics Rose This Week
The company's lead pipeline candidate is making news.
Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month
Following huge swings over the last two months, the biotech stock is now up 67% year to date.
Why Protagonist Therapeutics Stock Plunged Today
The FDA has placed a clinical hold on testing of rusfertide.
Why Protagonist Therapeutics Stock Is Tanking Today
The FDA put a clinical hold on one of the biotech's new drug candidates.
3 Small-Cap Biotech Stocks That Surged Last Week
Here's what's behind their impressive market performances.
Why Protagonist Therapeutics Is Skyrocketing Today
The company is set to start a pivotal study for one of its lead pipeline candidates.
Biotech’s Year-End To-Do List
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
Valuation
Earnings Transcripts
Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2020 Earnings Call Transcript
PTGX earnings call for the period ending March 31, 2020.
Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript
PTGX earnings call for the period ending March 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.